MicardisPlus is specifically indicated for the long-term management of essential hypertension (high blood pressure) in adult patients. Its primary use is in therapeutic situations where blood pressure remains inadequately controlled using the single ingredient, telmisartan, alone.

Addressing Uncontrolled Arterial Pressure

This fixed-dose combination is commonly used across conditions presenting with the objective sign of uncontrolled arterial pressure, helping to address symptoms related to heightened physiological strain on the vascular system. The dual approach may assist in supporting stability and sustained control of blood pressure in situations where single-agent therapy is inadequate. The combination is primarily relevant in contexts marked by chronic systemic imbalance.

The therapeutic domain involves support for managing factors associated with long-term cardiovascular concerns, including for patient groups with associated risk factors like older age or diabetes. This treatment contributes to easing the overall risk linked to serious health concerns by consistently lowering and maintaining blood pressure within a healthy range.

“The goal is to maintain pressure within a healthy range, supporting general well-being during symptomatic phases.”

Quick Fact: Relief for Arterial Pressure MicardisPlus is used for managing conditions that are characterized by periods of heightened blood pressure that persist despite previous treatment, supporting long-term functional stability.

Regulatory References

1. European Union Public Assessment Report (EPAR)

Who Can and Cannot Use MicardisPlus?

This section details population eligibility rules for MicardisPlus (Telmisartan/Hydrochlorothiazide) as defined by official regulatory documentation. The medicine is primarily indicated for adult patients with essential hypertension whose blood pressure remains not adequately controlled on Telmisartan monotherapy alone.

---

Contraindicated Populations (Absolute Ban)

Classification	Restricted Groups
Severe Organ Impairment	Patients with severe renal impairment (creatinine clearance < 30 ml/min), severe hepatic impairment, cholestasis, or biliary obstructive disorders.
Reproductive Status	Women in the second and third trimesters of pregnancy.
Metabolic/Drug-Disease	Patients with refractory hypokalaemia, hypercalcaemia, or known hypersensitivity to the components or sulfonamide-derived substances.
Dual Blockade	Concomitant use with Aliskiren is contraindicated in patients with Type 2 Diabetes Mellitus or moderate to severe renal impairment (GFR < 60 ml/min/1.73 m^2).

---

Age and Conditional Use Rules

• Pediatric: Use in children and adolescents under 18 years of age is not recommended as safety and efficacy have not been established.
• Pregnancy/Lactation: Use is not recommended during the first trimester of pregnancy or while breastfeeding.
• Conditional Use: The medicine should be used with caution in patients with mild to moderate hepatic impairment or those who are volume or salt depleted.

Interactions with Other Medicines and Products

MicardisPlus (Telmisartan/Hydrochlorothiazide) has several officially documented interactions that primarily affect fluid and electrolyte balance, renal function, and the concentration of co-administered drugs.

Formal Regulatory Constraints

Interaction Type	Interacting Agent	Official Constraint
Contraindicated	Aliskiren	Prohibited in patients with Diabetes Mellitus or Moderate to Severe Renal Impairment (GFR < 60 mL/min/1.73 m2).
P-gp Transporter	Digoxin	Telmisartan is an inhibitor of P-glycoprotein, resulting in increased Digoxin plasma concentrations. Monitoring is required.
Clearance Reduction	Lithium	Generally not recommended due to reduced renal clearance, which increases the risk of toxicity.
Absorption Timing	Cholestyramine, Colestipol	Must be taken 4 hours before or 4 to 6 hours after the resin to prevent reduced absorption of the thiazide component.

Pharmacodynamic Interactions

Concurrent use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may lead to a reduced blood pressure lowering effect and an increased risk of renal impairment. Agents that affect potassium levels, such as Potassium-sparing Diuretics or Potassium Supplements, increase the risk of hyperkalemia, while substances like Corticosteroids or certain Laxatives may increase the risk of hypokalemia.

MicardisPlus is a combination drug that modulates the renin-angiotensin-aldosterone system (RAAS) and renal fluid dynamics through two distinct mechanistic pathways.

Telmisartan's Mechanism

Telmisartan functions as a competitive antagonist by selectively targeting the angiotensin II type 1 ( AT1) receptors located on vascular smooth muscle cells. By blocking the binding of angiotensin II to the AT1 receptor, it inhibits AT1-mediated signaling, resulting in the inhibition of vasoconstriction . The consequence of this blockade is vasodilation, which decreases systemic vascular resistance. Telmisartan also increases the activity of the peroxisome proliferator-activated receptor gamma ( PPARgamma), thereby affecting associated metabolic pathways.

Hydrochlorothiazide's Mechanism

Hydrochlorothiazide ( HCTZ) acts within the distal convoluted tubule of the kidney. It specifically inhibits the sodium-chloride cotransporter ( NCC) , leading to decreased reabsorption of Na^+ and Cl^- ions. This inhibition increases the osmotic pressure within the lumen, promoting the retention of water and consequently increasing water excretion. The combination of these two actions increases natriuresis and diuresis, complementing the reduction in vascular tone.

How to Use MicardisPlus (Telmisartan/Hydrochlorothiazide)

This section outlines the administration guidelines for MicardisPlus tablets.

Administration and Dosage

Guideline	Instruction
Route of Administration	The medicine must be taken orally.
Dosing Schedule	The recommended dose is one tablet once daily.
With or Without Food	The tablet may be taken with or without food.
Preparation	Swallow the tablet whole with liquid. Do not chew or crush.
Special Handling	The tablet must be kept in its sealed blister pack until immediately before administration.

Population-Specific Use Rules

Specific rules are defined for certain patient populations:

• Pediatric Population: Use in children and adolescents (under 18 years) is not recommended as safety and efficacy have not been established.
• Elderly: No dose adjustment is generally required for older patients.
• Hepatic Impairment: Use is contraindicated in severe hepatic impairment. For mild to moderate impairment, the maximum dose of the telmisartan component must not exceed 40 mg once daily (i.e., only 40 mg/12.5 mg combination).
• Renal Impairment: Use is contraindicated in severe renal impairment (creatinine clearance < 30 mL/min).

The structure of these rules mandates a standardized, once-daily oral treatment regimen. The specific handling and limitations for certain groups are intended to ensure the medicine is administered only under designated conditions.

Research evidence / Overview of studies for MicardisPlus

Evidence for Essential Hypertension Not Controlled by Monotherapy

The primary clinical research on the MicardisPlus combination was conducted using Randomized Controlled Trials (RCTs). This design is widely used in the evaluation of medicinal products. These short-term studies examined the combination in adult patients whose blood pressure remained elevated even after treatment with Telmisartan alone. The research compared the fixed-dose combination against Telmisartan by itself and against an inactive substance. Studies monitored outcomes related to physiological strain or stress, focusing on the precise measurement of seated Systolic and Diastolic Blood Pressure (SBP/DBP). The findings describe patterns where adding the second component was associated with distinct, measured changes in blood pressure, compared to the single ingredient alone.

Long-Term Data and Follow-Up Duration

The duration of the main clinical efficacy studies was limited, typically involving short timeframes of around eight weeks. The evidence describes data collected regarding short-term changes in blood pressure, which is considered a surrogate endpoint in medicine. However, the longer-term health outcomes associated with this combination remain an area of limited evidence from dedicated controlled trials. Research has not directly determined whether the combination is associated with preventing major long-term events, such as a heart attack or stroke. The context regarding cardiovascular protection relies on the general observed effects of consistently lowering blood pressure, rather than direct evidence from long-term trials specific to this combination.

Evidence in Specific Patient Groups and Limitations

The research examined data on how the drug's parameters were measured in certain patient subgroups, including older adults (65 years and over) and those with conditions like Type 2 Diabetes. While the available evidence was evaluated in these specific settings, the data for other certain groups remain insufficient. The research is based on outcomes monitoring physiological strain or stress (blood pressure readings), which serve as markers for long-term health risk. A key limitation noted is the absence of dedicated, long-term controlled trials that examine outcomes related to the prevention of fatal or non-fatal cardiovascular events specifically for the fixed-dose combination. This means the research describes group patterns, but it does not determine whether an individual will respond similarly.

Common questions about MicardisPlus (FAQ)

---

Q: What is MicardisPlus used for?

A: MicardisPlus is a medication that includes two active ingredients, telmisartan and hydrochlorothiazide. It is indicated for the management of high blood pressure (hypertension) in patients whose blood pressure is not adequately controlled by telmisartan alone or hydrochlorothiazide alone.

---

Q: How does MicardisPlus work in the body?

A: The medication is a combination product. Telmisartan is an angiotensin II receptor blocker (ARB) that acts to help relax blood vessels. Hydrochlorothiazide is a diuretic (water pill) that works by increasing the excretion of salt and water by the kidneys. These two actions are intended to work together to lower blood pressure.

---

Q: What should I discuss with my healthcare provider before starting this medication?

A: It is important to discuss your full medical history with your provider, especially if you have ever had kidney disease, liver disease, congestive heart failure, lupus, or glaucoma. You should also mention all other medications, vitamins, and supplements you are currently taking to check for potential interactions.

---

Q: Are there serious side effects associated with MicardisPlus?

A: As with any medication, side effects are possible. Serious, though less common, effects that should be immediately reported to a healthcare professional include signs of a severe allergic reaction, symptoms of kidney problems, or low blood pressure (hypotension) which may cause dizziness or fainting.

Storage Requirements

MicardisPlus (telmisartan and hydrochlorothiazide) tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).

Due to the tablets' hygroscopic nature (sensitivity to moisture), it is officially required to keep the medicine in its original sealed blister pack and remove the tablet only immediately before administration.

Child Safety and Disposal

For safety, the medication must be stored out of the reach of children.

Proper disposal of unused or expired tablets should follow instructions from a healthcare provider or pharmacist, or local medicine take-back programs. Official regulatory guidelines emphasize that the medication is harmful to aquatic life and must not be released into the environment.